SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network ($AVT) is trending as the community discusses its potential and notes its listing on Coinbase and Mexc. Excitement is building around strategic partnerships and its role in enterprise blockchain solutions. Some community members are speculating on potential price movements and future growth.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around the project, energized by its listing on Jupiter and the low cost to become a millionaire in $UPDOG. Community members are actively asking, "What's UpDog?" and highlighting the project's strong community vibes and joke-meta pioneer status on the Solana network. The $UPDOG community is also celebrating collaborations and cross-community support with $BROKE and $WAGMI.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Fueled by a recently closed $75M investment, POET Technologies is trending as the community speculates on the identity of the institutional investor, with some hoping it's a major player like NVDA. Bullish sentiment is further supported by POET's Optical Interposer platform, touted for its potential to revolutionize AI data centers with increased processing speed and reduced power consumption, positioning the company as a key player in the burgeoning AI connectivity sector. The community is also discussing potential acquisitions and new partnerships.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending as the stock rallies, fueled by a new multi-launch contract and potential upside from government contracts. The community is buzzing about continued accumulation by institutional investors and the possibility of a gamma squeeze, while also debating valuation concerns amid the recent surge.  Enthusiasm remains high for the company's long-term prospects, particularly related to the Neutron launch and potential for space-based laser communication capabilities.

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

ATON is trending due to its unique position as a Nasdaq-listed company focused on building a digital asset treasury on the TON blockchain within Telegram, attracting attention from traders looking for the next low-float runner. Community discussions revolve around its potential for significant gains, drawing comparisons to other high-flying stocks with similar characteristics. The company's strategy and leadership, particularly its ties to the crypto world, are also sparking interest.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Galecto Inc. is trending due to a significant surge in price and volume, reminiscent of other recent low-float runners. The community is actively discussing potential short squeezes, high borrowing rates, and the stock's limited float, contributing to its volatile price action. Some traders caution about pump-and-dump dynamics, while others anticipate further upward momentum.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

UPC is trending as traders discuss its low float, substantial cash reserves, and potential for a significant breakout. The community is speculating on possible upcoming news or a strategic move that could trigger a rally, while also drawing comparisons to other recently volatile low-float stocks. Some investors believe the company is undervalued given its assets, while others are wary due to its history.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid community discussions about positive data, a potential short squeeze, and speculation around a buyout. Investor confidence seems to be returning, with many highlighting the stock's undervaluation and upcoming catalysts like conference presentations and earnings. Community members are closely watching resistance levels and expressing optimism about the stock's long-term potential.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

$TMC is trending as the deep-sea mining sector gains traction, with community members discussing potential short squeezes and a possible breakout. Optimism is fueled by anticipation of government partnerships and regulatory approvals, particularly the NOAA decision. Bullish investors are focused on the company's long-term potential in the critical minerals market.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

AVGO is trending as investors discuss its AI prospects and potential competition following news of partnerships between OpenAI and other chipmakers like AMD. Community members are debating the impact of these deals on Broadcom's market share and its strategic positioning in the AI landscape. Despite some bearish sentiment, many bulls remain confident in AVGO's long-term growth, citing strong fundamentals and a possible rebound after recent consolidation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LakeShore Biopharma Co., Ltd (LSB) on Thursday announced that its board of directors has received a revised preliminary non-binding proposal letter from a consortium to acquire all of the outstanding ordinary shares of the company in an all-cash transaction for $0.86 per ordinary share.The consortium is comprised of Oceanpine Investment Fund II LP, Oceanpine Capital Inc., and Crystal Peak Investment Inc. Members of the consortium currently beneficially own in aggregate approximately 52.1% of the company's issued and outstanding ordinary shares.The revised proposal letter, dated August 26, revises the preliminary non-binding proposal letter dated August 18, previously received from Oceanpine Capital.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LSB">LSB stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.LakeShore <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-receipt-of-a-revised-preliminary-non-binding-proposal-to-acquire-the-company-and-formation-of-special-committee-302541021.html">said</a> its board has formed a special committee consisting of its three independent directors, Adam Zhao, Thomas Xue, and Chunyang Shao, to evaluate and consider the revised proposal letter and transaction.The company has not made any decisions regarding its response to the proposal, it said, while adding that there is no assurance that a definitive offer will be made or an agreement executed.LakeShore said that the proposed purchase price per share of $0.86, which represents a premium of about 9% from the stock’s closing price on Wednesday, remains unchanged from the original proposal.The members of the consortium, however, have entered into an agreement to vote all of their shares in favor of the proposed transaction. They also do not intend to sell their shares to any third party or support any competing bid while remaining members of the consortium, LakeShore said.LSB stock is down by 77% this year and by 82% over the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-gdp-3-3-in-q2-revised-upwards-from-3/chs6JFbRdmZ">GDP Grows At 3.3% In Q2, Economy Expands At A Faster Clip Than Previously Estimated</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

LakeShore Biopharma Receives Revised Proposal To Acquire Company

The company said the revised preliminary non-binding letter proposes the acquisition of all outstanding ordinary shares in an all-cash transaction for $0.86 apiece.

Equity

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee LakeShore Biopharma Announces Receipt of a Revised...

LakeShore Biopharma Co. (LSB) on Monday said that its board received a preliminary non-binding proposal letter to acquire all of the outstanding ordinary shares of the company for $0.86 per share.The proposal from Oceanpine Investment Fund II LP and Oceanpine Capital Inc. was dated August 18 and is for all shares not currently owned by Oceanpine Capital, the company said. The price of $0.86 represents a premium of 10.3% to the stock’s closing price on August 15.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-receipt-of-a-preliminary-non-binding-proposal-to-acquire-the-company-302532192.html">said</a> that the board will carefully review and evaluate the proposal to determine the future course of action. However, the board has not made any decisions on the proposal, and there is no assurance that any agreement will be executed, it added.On Stocktwits, retail sentiment about <a href="https://stocktwits.com/symbol/LSB">LakeShore</a> trended in the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Shares of the company traded 1% higher in the pre-market session at the time of writing.The proposed transaction will be funded with rollover equity and available cash on hand and will not be subject to a financing condition, Oceanpine said in its letter. “While we are fully prepared to work collaboratively with the Board to pursue the proposed transaction in a timely manner, we are open to exploring potential alternative structures of the Proposed Transaction to expedite the process of delivering value to the Company's shareholders,” Oceanpine said in its letter.LakeShore Biopharma operates in China, Singapore, and the Philippines. Its main product is a freeze-dried human rabies vaccine.LSB stock is down by 77% this year and by about 83% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tonix-pharma-stock-rises-pre-market-after-fda-approval-for-drug/chsO9FfRdXb">This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

LakeShore Biopharma Just Got An Acquisition Proposal From Oceanpine Capital: More Details Inside 

The offer price of $0.86 represents a premium of 10.3% to the company's last closing price on August 15.

LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance LakeShore Biopharma Reports Unaudited Financial Results for the First...

LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire GAITHERSBURG, Md., Oct...

LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance

LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and...

LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation PR Newswire...

Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024

Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024...

LakeShore Biopharma Announces Leadership Transitions

LakeShore Biopharma Announces Leadership Transitions LakeShore Biopharma Announces Leadership Transitions PR Newswire GAITHERSBURG, Md., Sept. 4, 2024 GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire...

LakeShore Biopharma Announces Financial Results for Fiscal Year 2024

LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 PR Newswire GAITHERSBURG, Md., Aug. 15, 2024 Gross margin...

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

LakeShore Biopharma Co Ltd.

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

LSB LakeShore Biopharma Co Ltd.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest LSB News